A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

BACKGROUND: Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within different types of epithelial tumors. This phase 1 dose e...

Descripción completa

Detalles Bibliográficos
Autores principales: Machiels, Jean-Pascal, Salazar, Ramon, Rottey, Sylvie, Duran, Ignacio, Dirix, Luc, Geboes, Karen, Wilkinson-Blanc, Christine, Pover, Gillian, Alvis, Simon, Champion, Brian, Fisher, Kerry, McElwaine-Johnn, Hilary, Beadle, John, Calvo, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348630/
https://www.ncbi.nlm.nih.gov/pubmed/30691536
http://dx.doi.org/10.1186/s40425-019-0510-7

Ejemplares similares

Ejemplares similares